Jann Ludwig Mueller-Gomez
Research Subjects
Jann Ludwig Mueller-Gomez has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hala Ibrahim Thaalibi
Toufik’s World Medical Association, Sumy, Ukraine
2 shared publications - Toufik Abdul-Rahman
Toufik’s World Medical Association, Sumy, Ukraine
2 shared publications - Emmanuel James
Toufik’s World Medical Association, Sumy, Ukraine
1 shared publication - Evelyn Faith Ogungbemi
Rostov State Medical University, Rostov-on-Don, Russian Federation
1 shared publication Gargi Gautam
Toufik’s World Medical Association, Sumy, Ukraine
1 shared publication- Godfred Yawson Scott
Department of Medical Diagnostics, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
1 shared publication
Latest Publications
- Open Access
- 1 July 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Evaluating the potential of salivary biomarkers in amyotrophic lateral sclerosis: a promising frontier for early diagnosis and disease monitoring
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the degeneration of upper and lower motor neurons and is associated with a poor prognosis due to the absence of effective disease-modifying treatments. Diagnosis remains challenging, as early symptoms are subtle and may overlap with other neurological conditions. Current diagnostic methods—clinical evaluation, electrophysiology, neuroimaging, and exclusion of alternative etiologies—are frequently applied only after significant disease progression. Although current and emerging biomarkers improve diagnostic accuracy, most require invasive collection of cerebrospinal fluid or blood. This review explores the potential of saliva as a reliable, accessible and non-invasive biofluid for ALS biomarker discovery. Saliva reflects systemic physiological states through its diverse molecular constituents, including proteins, metabolites, nucleic acids, and inflammatory markers. Specific candidates show promise: salivary chromogranin A may correlate with disease severity, while salivary cortisol reflects the emotional and physiological stress associated with ALS. Additionally, proteomic profiling, spectroscopic analyses, and extracellular vesicle characterization may reveal broader molecular signatures with diagnostic and prognostic value. Despite these promising findings, significant challenges remain, including the lack of standardized collection and analysis protocols, inherent variability in salivary composition, and limited large-scale clinical validation. Further research is needed to establish salivary biomarkers as a robust component of the ALS diagnostic and monitoring framework, with the potential to improve early detection and long-term patient outcomes.
- 1 July 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessEvaluating the potential of salivary biomarkers in amyotrophic lateral sclerosis: a promising frontier for early diagnosis and disease monitoring
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the degeneration of upper and lower motor neurons and is associated with a poor prognosis due to the absence of effective disease-modifying treatments. Diagnosis remains challenging, as early symptoms are subtle and may overlap with other neurological conditions. Current diagnostic methods—clinical evaluation, electrophysiology, neuroimaging, and exclusion of alternative etiologies—are frequently applied only after significant disease progression. Although current and emerging biomarkers improve diagnostic accuracy, most require invasive collection of cerebrospinal fluid or blood. This review explores the potential of saliva as a reliable, accessible and non-invasive biofluid for ALS biomarker discovery. Saliva reflects systemic physiological states through its diverse molecular constituents, including proteins, metabolites, nucleic acids, and inflammatory markers. Specific candidates show promise: salivary chromogranin A may correlate with disease severity, while salivary cortisol reflects the emotional and physiological stress associated with ALS. Additionally, proteomic profiling, spectroscopic analyses, and extracellular vesicle characterization may reveal broader molecular signatures with diagnostic and prognostic value. Despite these promising findings, significant challenges remain, including the lack of standardized collection and analysis protocols, inherent variability in salivary composition, and limited large-scale clinical validation. Further research is needed to establish salivary biomarkers as a robust component of the ALS diagnostic and monitoring framework, with the potential to improve early detection and long-term patient outcomes.
- Open Access
- 11 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1495-1510
The emergence of Clade IIb and Ib mpox viruses: a state-of-the-art review
Mpox, a zoonotic Orthopoxvirus infection, was historically endemic to West and Central Africa. In 2022, it sparked a significant global outbreak, raising concerns about its spread beyond traditional regions. Notably, the emergence of Clade IIb and Ib strains has alarmed the global health community due to their increased transmission among humans. This paper examines mpox viruses and their general characteristics, their evolution, and the emergence of novel clades with unique features. Clade IIb stands out for its unique genetic mutations, which may enhance its transmissibility. Clinically, infections often present with fewer anogenital lesions and milder symptoms, which can complicate diagnosis. PCR testing remains the most reliable diagnostic tool, although emerging point-of-care tests show promise. Treatments such as tecovirimat and immune-based therapies (e.g., VIGIV) have demonstrated success, despite limitations. The MVA vaccine provides partial protection, although its efficacy against Clade IIb requires further validation. The emergence of Clades IIb and Ib, with distinct transmission dynamics, especially among specific population groups, underscores the need for targeted public health responses. This review highlights critical surveillance challenges in endemic African regions, where underreporting and limited diagnostic infrastructure hinder early detection. By analyzing the evolution and spread of newer clades, this review provides unique insights into mpox’s shifting epidemiology and outlines implications for global preparedness, including the urgent need for strengthened surveillance systems, equitable access to vaccines, and coordinated international efforts focusing on research and preparedness to help mitigate future risks.
- 11 December 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1495-1510
Open AccessThe emergence of Clade IIb and Ib mpox viruses: a state-of-the-art review
Mpox, a zoonotic Orthopoxvirus infection, was historically endemic to West and Central Africa. In 2022, it sparked a significant global outbreak, raising concerns about its spread beyond traditional regions. Notably, the emergence of Clade IIb and Ib strains has alarmed the global health community due to their increased transmission among humans. This paper examines mpox viruses and their general characteristics, their evolution, and the emergence of novel clades with unique features. Clade IIb stands out for its unique genetic mutations, which may enhance its transmissibility. Clinically, infections often present with fewer anogenital lesions and milder symptoms, which can complicate diagnosis. PCR testing remains the most reliable diagnostic tool, although emerging point-of-care tests show promise. Treatments such as tecovirimat and immune-based therapies (e.g., VIGIV) have demonstrated success, despite limitations. The MVA vaccine provides partial protection, although its efficacy against Clade IIb requires further validation. The emergence of Clades IIb and Ib, with distinct transmission dynamics, especially among specific population groups, underscores the need for targeted public health responses. This review highlights critical surveillance challenges in endemic African regions, where underreporting and limited diagnostic infrastructure hinder early detection. By analyzing the evolution and spread of newer clades, this review provides unique insights into mpox’s shifting epidemiology and outlines implications for global preparedness, including the urgent need for strengthened surveillance systems, equitable access to vaccines, and coordinated international efforts focusing on research and preparedness to help mitigate future risks.